FDA Approved: SURVANTA — Supplemental Application (AbbVie Inc.)

View source ↗

Summary

The FDA approved a supplemental application for SURVANTA (beractant) by AbbVie, authorizing changes to its labeling and/or indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome in Preterm Infants

Drugs mentioned

• SURVANTA (beractant)

Snippet

SUPPL AP for SURVANTA (BERACTANT)